# Insulin Glargine U300 vs Insulin Degludec U100 in Impact on the Glycaemic and Cardiovascular Factors

> **NCT04692415** · PHASE4 · COMPLETED · sponsor: **University of Split, School of Medicine** · enrollment: 25 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Degludec
- **DRUG:** Glargine U300

## Key facts

- **NCT ID:** NCT04692415
- **Lead sponsor:** University of Split, School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-15
- **Primary completion:** 2019-06-27
- **Final completion:** 2019-06-27
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2020-12-31

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04692415

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04692415, "Insulin Glargine U300 vs Insulin Degludec U100 in Impact on the Glycaemic and Cardiovascular Factors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04692415. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*